Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,284,000 | 2,576,000 | 5,963,000 | 4,728,000 | 4,626,172 |
| Depreciation Amortization | 1,548,000 | 1,719,000 | 2,782,000 | 3,044,000 | 2,624,305 |
| Accounts receivable | -195,000 | -113,000 | 36,000 | -670,000 | -394,665 |
| Other Working Capital | -490,000 | -1,237,000 | -1,859,000 | 1,000 | 658,784 |
| Other Operating Activity | 528,000 | 379,000 | 2,392,000 | 1,867,000 | 1,221,385 |
| Operating Cash Flow | $3,675,000 | $3,324,000 | $9,314,000 | $8,970,000 | $8,735,981 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,077,000 | -1,145,000 | -1,795,000 | -1,491,000 | -1,015,075 |
| Net Acquisitions | -3,312,000 | -580,000 | -706,000 | -273,000 | -9,433,243 |
| Purchase Of Investment | -1,507,000 | -10,064,000 | -11,998,000 | -5,110,000 | -805,932 |
| Sale Of Investment | 5,624,000 | 7,839,000 | 8,936,000 | 5,649,000 | 954,361 |
| Other Investing Activity | 70,000 | 21,000 | 3,000 | 1,886,000 | -1,888,431 |
| Investing Cash Flow | $-202,000 | $-3,929,000 | $-5,560,000 | $661,000 | $-12,188,320 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,343,000 | 2,086,000 | 784,000 | -1,965,000 | -203,854 |
| Debt Issued | 0 | 9,000 | 14,700,000 | 1,000,000 | 4,000,000 |
| Debt Repayment | -577,000 | -303,000 | -11,071,000 | -3,012,000 | -1,673,998 |
| Common Stock Issued | 429,000 | 395,000 | 1,850,000 | 969,000 | 328,411 |
| Common Stock Repurchased | -2,195,000 | -1,605,000 | -2,364,000 | -77,000 | -866,825 |
| Dividend Paid | -1,342,000 | -882,000 | -3,183,000 | -2,938,000 | -2,671,475 |
| Other Financing Activity | -400,000 | -6,396,000 | -521,000 | -400,000 | 0 |
| Financing Cash Flow | $-2,742,000 | $-6,696,000 | $195,000 | $-6,423,000 | $-1,087,741 |
| Exchange Rate Effect | -143,000 | -26,000 | 40,000 | -43,000 | -620,893 |
| Beginning Cash Position | 3,475,000 | 10,802,000 | 6,813,000 | 3,648,000 | 8,809,339 |
| End Cash Position | 4,063,000 | 3,475,000 | 10,802,000 | 6,813,000 | 3,648,371 |
| Net Cash Flow | $588,000 | $-7,327,000 | $3,989,000 | $3,165,000 | $-5,160,968 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,675,000 | 3,324,000 | 9,314,000 | 8,970,000 | 8,735,981 |
| Capital Expenditure | -1,077,000 | -1,145,000 | -1,795,000 | -1,491,000 | -1,015,075 |
| Free Cash Flow | 2,598,000 | 2,179,000 | 7,519,000 | 7,479,000 | 7,720,906 |